GSK to use BioClinica Interactive Web Response solution
The pharma giant has signed a multi-year agreement for global trial management technology
GlaxoSmithKline (GSK) has agreed a multi-year enterprise technology deal with US-based BioClinica, enabling it to deploy BioClinica’s Trident IWR (Interactive Web Response) system across its Phase I-IV clinical trials.
Mark Weinstein, ceo of BioClinica, a global provider of integrated, technology-enhanced clinical trial management services located in Newtown, PA, said: ‘GSK had a requirement for a new solution to enable internal staff to configure and manage highly complex IWR clinical studies, and we are pleased GSK chose Trident.’
Trident IWR’s design provides clinical operations personnel with an intuitive way to directly set up, monitor, and maintain randomisation and supplies for their clinical trials, in a fraction of the time previously required.
According to BioClinica, it delivers rapid study setup without the need for programming, while simultaneously delivering world-class IVR (Interactive Voice Response) system phone support through the same simplified configuration process.
BioClinica has also just established a partnership NJ-based CRO, Symbiance.